Fig. 2

Trends in 1 L treatment for mRCC by drug class and route of administration (2006–2015). a Trends by drug class and route of administration. TK/VEGF inhibitors included sunitinib, pazopanib, sorafenib, axitinib and bevacizumab ± IFN-α. mTOR treatments included temsirolimus and everolimus. Orally administered agents included sunitinib, pazopanib, sorafenib, axitinib and everolimus; IV treatments included bevacizumab ± IFN-α, temsirolimus and interleukin 2. For the oral (blue line) vs IV (orange line) comparison, the percentage of each group sums to 100% for each year. For the TK/VEGF (grey line) vs mTOR (yellow line) comparison, the percentage of each group may sum to < 100% because interleukin 2 was not included (accounts for < 1% of patients in each year). b Trends by individual treatment. Trends are plotted as a single value for the entire year, and approximate timings for US FDA approvals are indicated by diamond symbols in part b (pre-2006 approvals are shown adjacent to the y-axis). Approvals plotted include 1 L sunitinib (January 26, 2006), 1 L pazopanib (October 19, 2009), 2 L sorafenib (December 20, 2005), 2 L axitinib (January 27, 2012), 1 L bevacizumab ± IFN-α (July 31, 2009), 1 L temsirolimus (May 30, 2007), 2 L everolimus (March 30, 2009) and 1 L interleukin 2 (May 5, 1992). In each given year, the percentage of patients receiving each indicated agent sums to 100%